Ask whether men or women do better on GLP-1s and the internet will answer instantly, confidently, and from material the prescribing information does not contain. The labels themselves are quieter, and their quietness has a shape. Across the class, every statement about efficacy and sex is a statement that the effect was consistent across subgroups, and no label anywhere publishes a separate average weight loss for men and for women. Those are different claims. Teasing them apart is a lesson in reading subgroup language, and the lesson transfers to every label you will ever open, which is why How to Read Your GLP-1's Prescribing Information is the companion page to this one.
What the efficacy sections actually say
The wording is nearly identical across the class, and it is worth reading slowly. The Wegovy label, for its weight trials, states that a reduction in body weight was observed “irrespective of” age, sex, race, ethnicity, BMI at baseline, body weight at baseline, and level of renal function impairment. For its cardiovascular outcomes trial, the reduction of MACE “was not impacted by” the same list. Zepbound says a reduction in body weight was observed “irrespective of” age, sex, race, ethnicity, baseline BMI and glycemic status, and for its sleep apnea studies the reduction in AHI was likewise observed irrespective of age, sex, ethnicity, baseline BMI or baseline severity. Ozempic says efficacy “was not impacted by” age, gender, race, ethnicity, BMI at baseline, body weight at baseline, diabetes duration and level of renal function impairment. Mounjaro says effectiveness “was not impacted by” age, gender, race, ethnicity, region, or baseline BMI, HbA1c, diabetes duration or renal function.
Notice what is not there. No table of average weight loss by sex. No percentage for women, no percentage for men. A consistency statement says the effect was there in both groups; it does not say the two groups had the same number, and it does not publish either number. Anyone quoting a figure for how much men versus women lose on semaglutide is quoting from somewhere other than the label.
What the body does with the drug
The pharmacokinetics sections run in the same direction. The Wegovy label reports no clinically significant differences in semaglutide pharmacokinetics based on age, sex, race, ethnicity, body weight, upper GI disease or renal impairment. The Zepbound label states that age, sex, race, ethnicity and body weight do not have a clinically relevant effect on tirzepatide pharmacokinetics. The Ozempic label agrees on sex, and adds the one intrinsic factor that does move: the exposure of semaglutide decreases as body weight increases. So within these labels, the patient characteristic that measurably changes how much drug is in the body is body weight, not sex. Why any difference might exist, in exposure or in response, is a mechanism question the labels do not address, and no mechanism can be read out of a sentence that reports only consistency.
GLP 1 Tracker AppYour own trend, on your own phone: weight logged day by day, no account, nothing collected. The number that answers your questions is yours.
Get the app
Where the labels do split by sex: adverse reactions
Here is the inversion worth sitting with. Efficacy gets a consistency statement, but adverse reactions get actual splits, and hair loss is the clearest example. The Wegovy label, pooling its weight studies at 2.4 mg, reports hair loss in 3.3 percent overall on drug versus 1 percent on placebo, broken down as 4 percent of female patients and 0.9 percent of male patients on Wegovy, against 2 percent female and 0 male on placebo. In the 7.2 mg trials the same pattern repeats: 8.4 percent female and 0.2 percent male on 7.2 mg, 5.4 percent female and 0 male on 2.4 mg, and 1.5 percent female and 0 male on placebo. Zepbound reports hair loss more frequently in female than male patients: 7.1 percent female versus 0.5 percent male on drug, and 1.3 percent female versus 0 percent male on placebo.
Read those the way the tables demand. Each split carries its placebo column, and in both datasets the placebo rate is also higher in women, 2 percent against 0 in one, 1.3 percent against 0 in the other. A split without its control arm cannot be interpreted, because the background rate differs between the groups before the drug enters the picture. That is the transferable lesson, and it applies to every sex-split number you will meet in a forum. The Wegovy label also reports more hip and pelvis fractures on drug than placebo in female patients in its cardiovascular outcomes trial, a finding covered in full at Rapid Weight Loss and Your Bones. The pattern of shedding itself, what it feels like and how it runs its course, is the subject of Hair Shedding During Rapid Weight Loss: What the Data Says.
Who was actually in the trials
There is a fact about these trials that changes how any average should be read, and the labels state it plainly in their baseline tables. The weight-loss trials were majority women: Wegovy's studies report 71, 74, 76 and 81 percent female, and Zepbound's two main weight studies were 37 percent male, which is to say 63 percent female. The trials that skew male are the ones asking a different question entirely; Wegovy's cardiovascular outcomes trial was 72 percent male, and Zepbound's second sleep apnea study was 72 percent male. So the headline weight-loss averages come from populations that were roughly seven in ten women. That is worth knowing when you compare your own trajectory to a headline number, and it is not itself a finding about sex; it is a fact about recruitment.
What a subgroup can and cannot tell you
All of which arrives at the one durable point. A subgroup average is still an average, and an average predicts nothing about one person. A label saying an effect held irrespective of sex is telling you the effect was not confined to one group; it is not telling you what either group's number was, still less what yours will be. Individual variation is enormous on these medicines, and it is treated clinically, not statistically, at Not Responding to Your GLP-1? What the Trials Call It. The alternative to borrowing a subgroup's number is generating your own: How to Read a Weight Trend Line covers reading weeks of your own data for the signal, which is the only dataset in this conversation that contains you.
Frequently asked questions
Do men or women lose more weight on GLP-1 medications?
No GLP-1 label publishes a separate average weight loss for men and for women, so no comparison exists in the prescribing information. What the labels publish instead is a consistency statement, saying a reduction in body weight was observed irrespective of sex alongside age, race, ethnicity and other baseline factors. That confirms the effect was present in both groups without saying what either group's number was.
What does irrespective of sex mean in a drug label?
It is a consistency statement, not a comparison. The label is telling you the effect was observed across those subgroups rather than confined to one of them. It is not telling you the amounts were identical, not publishing separate averages, and not predicting anything about one person's response.
Are GLP-1 side effects different for women than for men?
Where the labels do break results out by sex, it is in adverse reactions, not efficacy. Wegovy reports hair loss in 4 percent of female patients versus 0.9 percent of male patients on 2.4 mg, and Zepbound reports 7.1 percent female versus 0.5 percent male. In both datasets the placebo rate is also higher in women, which is why a split without its control arm cannot be interpreted.
Does semaglutide behave differently in women's bodies?
The pharmacokinetics sections say no clinically significant differences based on sex. Wegovy and Ozempic both state that sex does not meaningfully change semaglutide pharmacokinetics, and Zepbound says the same for tirzepatide. The intrinsic factor the Ozempic label does flag is body weight: semaglutide exposure decreases as body weight increases.
Were the GLP-1 weight-loss trials mostly women?
The weight-loss trials were majority women. Wegovy's studies report 71, 74, 76 and 81 percent female, and Zepbound's two main weight studies were 37 percent male, so headline averages come from populations that were roughly seven in ten women. The trials that skew male asked different questions: Wegovy's cardiovascular outcomes trial was 72 percent male.